Aptose Biosciences Meets Nasdaq Minimum Bid Price Compliance
Aptose Biosciences (NASDAQ: APTO), a clinical-stage precision oncology company, has regained compliance with Nasdaq's minimum bid price requirement. The company received confirmation from Nasdaq that its common shares maintained a closing bid price of $1.00 or higher for ten consecutive business days through March 14, 2025.
While this resolves the minimum bid price compliance issue, Aptose remains non-compliant with Nasdaq's $2.5 million shareholders' equity requirement. The company is currently operating under a Hearing Panel exception that provides additional time to meet this requirement, though compliance is not guaranteed.
Aptose is developing tuspetinib (TUS)-based triple drug frontline therapy for newly diagnosed acute myeloid leukemia (AML) patients.
Aptose Biosciences (NASDAQ: APTO), un'azienda di oncologia di precisione in fase clinica, ha riacquistato la conformità con il requisito del prezzo minimo di offerta di Nasdaq. L'azienda ha ricevuto conferma da Nasdaq che le sue azioni ordinarie hanno mantenuto un prezzo di chiusura di $1.00 o superiore per dieci giorni lavorativi consecutivi fino al 14 marzo 2025.
Sebbene questo risolva il problema di conformità relativo al prezzo minimo di offerta, Aptose rimane non conforme al requisito di $2.5 milioni di patrimonio netto degli azionisti di Nasdaq. L'azienda opera attualmente sotto un'eccezione del Comitato di Audizione che fornisce ulteriore tempo per soddisfare questo requisito, anche se la conformità non è garantita.
Aptose sta sviluppando una terapia di prima linea a base di tuspetinib (TUS) con tripla combinazione per pazienti con leucemia mieloide acuta (AML) recentemente diagnosticati.
Aptose Biosciences (NASDAQ: APTO), una compañía de oncología de precisión en etapa clínica, ha recuperado el cumplimiento con el requisito de precio mínimo de oferta de Nasdaq. La compañía recibió confirmación de Nasdaq de que sus acciones comunes mantuvieron un precio de cierre de $1.00 o más durante diez días hábiles consecutivos hasta el 14 de marzo de 2025.
Aunque esto resuelve el problema de cumplimiento del precio mínimo de oferta, Aptose sigue sin cumplir con el requisito de patrimonio neto de $2.5 millones de los accionistas de Nasdaq. La compañía está operando actualmente bajo una excepción del Panel de Audiencia que proporciona tiempo adicional para cumplir con este requisito, aunque el cumplimiento no está garantizado.
Aptose está desarrollando una terapia de primera línea basada en tuspetinib (TUS) con triple combinación para pacientes recientemente diagnosticados con leucemia mieloide aguda (AML).
Aptose Biosciences (NASDAQ: APTO), 임상 단계의 정밀 종양학 회사가 나스닥의 최소 입찰 가격 요건을 충족했습니다. 이 회사는 나스닥으로부터 자사의 보통주가 2025년 3월 14일까지 10일 연속으로 $1.00 이상의 종가를 유지했다는 확인을 받았습니다.
이로 인해 최소 입찰 가격 준수 문제는 해결되었지만, Aptose는 여전히 나스닥의 $250만 주주 자본 요건을 충족하지 못하고 있습니다. 이 회사는 현재 이 요건을 충족하기 위해 추가 시간을 제공하는 청문회 패널의 예외 아래 운영되고 있지만, 준수가 보장되지는 않습니다.
Aptose는 새롭게 진단된 급성 골수성 백혈병(AML) 환자를 위한 tuspetinib (TUS) 기반의 삼중 약물 1차 요법을 개발하고 있습니다.
Aptose Biosciences (NASDAQ: APTO), une entreprise de cancérologie de précision en phase clinique, a retrouvé sa conformité avec l'exigence de prix d'offre minimum de Nasdaq. L'entreprise a reçu confirmation de Nasdaq que ses actions ordinaires ont maintenu un prix de clôture de 1,00 $ ou plus pendant dix jours ouvrables consécutifs jusqu'au 14 mars 2025.
Bien que cela résolve le problème de conformité au prix d'offre minimum, Aptose reste non conforme à l'exigence de 2,5 millions de dollars en capitaux propres des actionnaires de Nasdaq. L'entreprise fonctionne actuellement sous une exception du Panel d'Audience qui fournit un temps supplémentaire pour répondre à cette exigence, bien que la conformité ne soit pas garantie.
Aptose développe une thérapie de première ligne à base de tuspetinib (TUS) avec une triple combinaison pour les patients récemment diagnostiqués avec une leucémie myéloïde aiguë (LMA).
Aptose Biosciences (NASDAQ: APTO), ein Unternehmen für präzise Onkologie in der klinischen Phase, hat die Einhaltung der Mindestgebotsanforderung von Nasdaq wiedererlangt. Das Unternehmen erhielt von Nasdaq die Bestätigung, dass seine Stammaktien über einen Zeitraum von zehn aufeinanderfolgenden Geschäftstagen bis zum 14. März 2025 einen Schlusskurs von 1,00 $ oder mehr gehalten haben.
Obwohl dies das Problem der Einhaltung des Mindestgebotspreises löst, bleibt Aptose nicht konform mit der Eigenkapitalanforderung von 2,5 Millionen Dollar von Nasdaq. Das Unternehmen operiert derzeit unter einer Ausnahmegenehmigung des Anhörungsgremiums, die zusätzliche Zeit zur Erfüllung dieser Anforderung bietet, obwohl die Einhaltung nicht garantiert ist.
Aptose entwickelt eine dreifache Medikamentenfronttherapie auf Basis von tuspetinib (TUS) für neu diagnostizierte Patienten mit akuter myeloischer Leukämie (AML).
- Regained compliance with Nasdaq minimum bid price requirement ($1.00)
- Received extension from Hearing Panel for equity compliance
- Still non-compliant with $2.5M shareholders' equity requirement
- Risk of potential Nasdaq delisting if equity compliance not achieved
SAN DIEGO and TORONTO, March 17, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing the tuspetinib (TUS)-based triple drug frontline therapy to treat patients with newly diagnosed acute myeloid leukemia (AML), today announced that it received a written notification from the Listing Qualifications Department of The Nasdaq Stock Market, LLC (“Nasdaq”) notifying the Company that it is in compliance with Nasdaq’s minimum bid price requirement.
On March 14, 2025, Nasdaq confirmed that, for ten consecutive business days, the closing bid price of the Company’s common shares has been
About Aptose
Aptose Biosciences is a clinical-stage biotechnology company committed to developing precision medicines addressing unmet medical needs in oncology, with an initial focus on hematology. The Company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities. The Company’s lead clinical-stage compound tuspetinib (TUS), is an oral kinase inhibitor that has demonstrated activity as a monotherapy and in combination therapy in patients with relapsed or refractory acute myeloid leukemia (AML) and is being developed as a frontline triplet therapy in newly diagnosed AML. For more information, please visit www.aptose.com.
Forward Looking Statements
This press release may contain forward-looking statements within the meaning of Canadian and U.S. securities laws, including statements relating to the Company’s plans, objectives, expectations and intentions and other statements including words such as “continue”, “expect”, “intend”, “will”, “should”, “would”, “may”, and other similar expressions. Such statements reflect our current views with respect to future events and are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by us are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. Many factors could cause our actual results, performance or achievements to be materially different from any future results, performance or achievements described in this press release. Such factors could include, among others: our ability to regain full compliance with Nasdaq listing requirements and other risks detailed from time-to-time in our ongoing quarterly filings, annual information forms, annual reports and annual filings with Canadian securities regulators and the United States Securities and Exchange Commission.
Should one or more of these risks or uncertainties materialize, or should the assumptions set out in the section entitled "Risk Factors" in our filings with Canadian securities regulators and the United States Securities and Exchange Commission underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this press release and we do not intend, and do not assume any obligation, to update these forward-looking statements, except as required by law. We cannot assure you that such statements will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. Investors are cautioned that forward-looking statements are not guarantees of future performance and accordingly investors are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty therein.
For further information, please contact:
Aptose Biosciences Inc.
Susan Pietropaolo
Corporate Communications & Investor Relations
201-923-2049
spietropaolo@aptose.com
FAQ
Has Aptose Biosciences (APTO) resolved its Nasdaq minimum bid price compliance issue in March 2025?
What other Nasdaq compliance issues does Aptose Biosciences (APTO) currently face?
What is Aptose Biosciences' (APTO) main drug development focus?
What are the current Nasdaq listing requirements affecting Aptose (APTO)?
